Working... Menu
Trial record 51 of 611 for:    PLG

4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01211899
Recruitment Status : Unknown
Verified September 2010 by Hallym University Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : September 30, 2010
Last Update Posted : October 5, 2011
Information provided by (Responsible Party):
Hallym University Medical Center

Brief Summary:
Data on 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene are limited in Asian patients with sepsis. Therefore, the investigators aim to prospectively investigate the incidence of 4G/5G polymorphism and its relationship with disseminated intravascluar coagulatin in patients with severe sepsis and septic shock.

Condition or disease
Severe Sepsis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 160 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Incidence and Prognosis of Disseminated Intravscular Coagulation in Patients Severe Sepsis and Septic Shock; Association With 4G/5G Polymorphism of PAI-1 Gene
Study Start Date : September 2010
Estimated Primary Completion Date : September 2012

Resource links provided by the National Library of Medicine

Biospecimen Retention:   Samples With DNA
Blood sample for 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients admitted to the ICU for severe sepsis or septic shock

Inclusion Criteria:

  • Adult patinents aged > 18 years, Patients satisfying the criteria by 2008 Surviving Sepsis Campagin, Patients who are determined as having a sepsis within 24 hours of ICU stay

Exclusion Criteria:

  • Do-not-resuscitate, cardiopulmonary resuscitation, ICU stay < 1 day, Refusal to participate in the study, Hematologic malignancy or liver cirrhosis (Child C), Congenital abnormality in coagulation system, Transfer from other ICUs or hospitals

Layout table for additonal information
Responsible Party: Hallym University Medical Center Identifier: NCT01211899     History of Changes
Other Study ID Numbers: f2000tj2
First Posted: September 30, 2010    Key Record Dates
Last Update Posted: October 5, 2011
Last Verified: September 2010

Keywords provided by Hallym University Medical Center:
plasminogen activator inhibitor,
disseminated intravascular coagulation,

Additional relevant MeSH terms:
Layout table for MeSH terms
Plasminogen Inactivators
Plasminogen Activator Inhibitor 1
Shock, Septic
Disseminated Intravascular Coagulation
Systemic Inflammatory Response Syndrome
Pathologic Processes
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhagic Disorders
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors